<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02144831</url>
  </required_header>
  <id_info>
    <org_study_id>MENA-TIA study</org_study_id>
    <nct_id>NCT02144831</nct_id>
  </id_info>
  <brief_title>The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack</brief_title>
  <acronym>MENA-TIA</acronym>
  <official_title>The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack.10 vs 30 Days of Combination ASA and Clopidogrel Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of the research is to determine if 10 days of dual anti-platelet treatment
      is as effective as 30 days of similar treatment in the prevention of stroke, myocardial
      ischemia (MI) and death in patients with TIAs and minor stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transient Ischemic Attacks (TIAs) are common, easily misdiagnosed, not investigated
      appropriately and are often harbingers of disabling strokes. A TIA is best defined as an
      episode of neurological dysfunction caused by focal ischemia that lasts for less than 24
      hours (very often less than an hour). Minor stroke (NIHSS of &lt;3) is often lumped together
      with TIAs. The distinction between minor ischemic stroke and TIA is unimportant in terms of
      prognosis. Numerous studies have shown that short-term risk of stroke is high after TIA and
      minor ischemic stroke, particularly in the first few days, even in patients treated with
      aspirin, the current standard of care. In patients with TIAs and minor stroke effective
      therapies can significantly reduce the overall burden of stroke if initiated immediately. The
      recently completed CHANCE study comprising more than 5000 patients with TIAs and minor stroke
      showed that a short course of combination antiplatelet medications (ASA+clopidogrel) for 3
      weeks significantly reduced the 90-day risk of stroke when compared to ASA treatment.

      There are three trials where patients with TIAs and minor strokes were treated early after
      onset of symptoms with combination treatment with clopidogrel and ASA versus ASA alone.
      FASTER was a pilot trial based in Canada (5). It evaluated clopidogrel (300 mg load and 75
      mg/day afterwards) on a background of aspirin in patients presenting within 24 hours of a TIA
      or minor stroke. The trial enrolled 392 patients. The risk of stroke (ischemic or
      hemorrhagic) at 90 days was 11% in those treated with aspirin alone and 7% in those treated
      with clopidogrel and aspirin, a non-significant 36% relative risk reduction (RRR) in this
      pilot trial (p=0.19). There were two Intra cerebral hemorrhages(ICHs) and these were both in
      patients treated with clopidogrel and ASA.

      The recently completed CHANCE trial (5170 patients enrolled within 24 hours of symptom-onset)
      from China showed that in patients with high-risk TIAs and minor strokes, there was a
      significant absolute reduction of early stroke at 90 days from 11.7 % to 8.2 % hazard ration
      (HR) 0.68, 95% Confidence interval (CI) 0.57-0.81; p&lt;0.001) in patients treated with a
      combination of ASA and clopidogrel for 21 days compared to ASA alone (13). Similar to the
      EXPRESS study (3), most of the strokes developed in the initial days following the TIA. The
      observation that strokes occur very early, as is evident from EXPRESS and CHANCE suggests
      that perhaps the vascular pathology responsible for the events begins to heal rapidly once
      antiplatelet therapy is initiated. This allows for the possibility that shorter duration
      combination antiplatelet therapy may also be as effective as the 21 days treatment in CHANCE
      or the 30 days treatment in the NIH funded POINT trial. A prospective study that compares the
      outcome of stroke, MI or death at 90 days in patients treated with 10 days or 30 days of dual
      antiplatelet therapy will therefore be very useful. If the shorter duration dual antiplatelet
      therapy is as effective as the longer duration dual antiplatelet treatment, this will result
      in lower costs and the lower risk of side effects in stroke prevention in high-risk TIA
      patients.

      Hypothesis:

      The short duration use of dual antiplatelet agents for 10 days is as effective as a longer
      duration of 30 days or longer. The shorter duration treatment will however result in fewer
      hemorrhagic complications.

      STUDY OBJECTIVES

      The Primary Specific Aim of this randomized, multicenter clinical trial is to determine
      whether a 10 day course of treatment with clopidogrel 75 mg/day by mouth after a loading dose
      of 600 mg is as effective a similar treatment for 30 days in improving survival free from
      ischemic vascular events (ischemic stroke, myocardial infarction, and ischemic vascular
      death) at 90 days when subjects are randomized within 24 hours of time last known free of new
      ischemic symptoms in patients receiving aspirin 50-325 mg/day as the long-term antiplatelet
      therapy.

      There will be several secondary aims of the study, including comparison of the risk of major
      and minor hemorrhage, the risk of recurrent TIAs or minor stroke at 10-day, 30-day and 90-day
      evaluations and the measuring severity of any stroke in the two arms in the 90 days of
      follow-up. The NIHSS will be used for assessment of the severity of the stroke.

      Participation Centers During the course of the trial, approximately 10-15 sites will enroll
      approximately 1200 subjects with TIA or minor ischemic stroke. Before enrolling subjects into
      the study, all collaborating sites will obtain approval from local institutional review
      boards (IRBs), which will have access to all study documentation and educational materials.

      Study Population The study will include both TIA and minor ischemic stroke. Neurological
      impairment at the time of enrollment is expected to be minimal since the deficits prompting
      diagnosis will have largely resolved. Vascular risk factors, including diabetes,
      hypertension, and coronary artery disease, are expected to be common.

      Pregnant women will be excluded from the study because the safety of clopidogrel is not
      established in this population, and this drug may increase risk of harm to the fetus. Women
      at risk for pregnancy (see Exclusion Criteria) will also be excluded. No other vulnerable
      population will be excluded from the study.

      TREATMENTS Study Drugs This randomized study is primarily designed to compare a
      clopidogrel/aspirin combination versus an aspirin alone regimen for 10 days versus 30 days.
      This is an open-label design. Patients and physicians will be aware of the study medications.

      Aspirin tablets will be open label with the dose in a range 50-325 mg daily determined by the
      treating physician. A dose of 162 mg daily x 5 days, followed by 81 mg daily will be strongly
      recommended.

      Clopidogrel treatment will be offered in the following manner:

      Day 1: 8 tablets of clopidogrel 75 mg (loading dose of 600 mg) From D2 to D10 or D2 to D30:
      one tablet of clopidogrel 75 mg

      All patients will be on ASA 50-325 for the 90 days until the final assessment. Assignment to
      a Treatment Group The randomization will take place locally. To keep the study simple,
      sequential subjects will be randomized to 10 days (even number recruitment) and 30 day (odd
      number recruitment). All centers will recruit competitively into the trial.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To test if 10 days of treatment with ASA and Clopidogrel has fewer complications than 30 days of similar treatment</measure>
    <time_frame>4 years prospective study</time_frame>
    <description>Initiation of dual anti platelet treatment in high risk TIA patients within 24 hours of presentation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>What is the feasibility and efficacy of the non-inferiority design</measure>
    <time_frame>4 years</time_frame>
    <description>If 10 days of dual anti platelet treatment has equal efficacy in stroke prevention as 30 days of dual anti platelet treatment in patients with recent high risk TIAs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study the incidence of hemorrhagic complications</measure>
    <time_frame>4 years</time_frame>
    <description>Safety outcome will be the measurement hemorrhagic complication within thirty days of initiation of treatment. To test if 10 days of treatment with ASA and Clopidogrel has fewer complications than 30 days of similar treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Transient Ischemic Attacks</condition>
  <condition>Minor Stroke</condition>
  <arm_group>
    <arm_group_label>anti-thrombotic treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>anti-thrombotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)</intervention_name>
    <description>comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel</description>
    <arm_group_label>anti-thrombotic treatment</arm_group_label>
    <arm_group_label>anti-thrombotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Neurologic deficit (based on history or exam) attributed to focal brain ischemia and
             EITHER:

             High risk TIA: Complete resolution of the deficit at the time of randomization AND
             age, blood pressure, clinical features, duration of TIA and presence of diabetes
             (ABCD2) score &gt;4 OR Minor ischemic stroke: residual deficit with NIHSS â‰¤3 at the time
             of randomization.

          2. Ability to randomize within 24 hours of time last known free of new ischemic symptoms.

          3. Head CT or MRI ruling out hemorrhage or other pathology, such as vascular
             malformation, tumor, or abscess, that could explain symptoms or contraindicate
             therapy.

          4. Ability to tolerate aspirin at a dose of 50-325 mg/day.

        Exclusion Criteria

          1. TIA symptoms limited to isolated numbness, isolated visual changes, or isolated
             dizziness/vertigo.

          2. In the judgment of the treating physician, a candidate for thrombolysis,
             endarterectomy or endovascular intervention, unless the subject declines both
             endarterectomy and endovascular intervention at the time of the evaluation for
             eligibility.

          3. Receipt of any intravenous or intra-arterial thrombolysis within 1 week prior to index
             event.

          4. Gastrointestinal bleed or major surgery within 3 months prior to index event. History
             of non-traumatic intracranial hemorrhage.

          5. Clear indication for anticoagulation (e.g., warfarin, heparin) anticipated during the
             study period (atrial fibrillation, mechanical heart valve, deep venous thrombosis,
             pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state).

          6. Qualifying ischemic event induced by angiography or surgery.

          7. Severe non-cardiovascular comorbidity with life expectancy &lt;3 months.

          8. Contraindication to clopidogrel or aspirin:

               -  Known allergy

               -  Severe renal (serum creatinine &gt;2 mg/dL) or hepatic insufficiency (prior or
                  concurrent diagnosis, with international normalized ratio (INR)&gt;1.5, or any
                  resultant complication, such as variceal bleeding, encephalopathy, or icterus)

               -  Hemostatic disorder or systemic bleeding in the past 3 months

               -  Current thrombocytopenia (platelet count &lt;100 x109/l) or
                  neutropenia/granulocytopenia (&lt;1 x109/l) o History of drug-induced hematologic or
                  hepatic abnormalities

          9. Anticipated requirement for long-term (&gt;10 days) nonstudy antiplatelet drugs (eg,
             dipyridamole, clopidogrel, ticlopidine), or non steroidal anti inflammatory drugs
             (NSAIDs) affecting platelet function (such as prior vascular stent or arthritis).

         10. Not willing or able to discontinue prohibited concomitant medications. Inability to
             swallow medications.

         11. At risk for pregnancy: premenopausal or postmenopausal woman within 12 months of last
             menses without a negative pregnancy test or not committing to adequate birth control
             (e.g., oral contraceptive, two methods of barrier birth control, or abstinence).

         12. Unavailability for follow-up. Signed and dated informed consent not obtained from
             patient.

        Other neurological conditions that would complicate assessment of outcomes during
        follow-up.

        Ongoing treatment in another study of an investigational therapy, or treatment in such a
        study within the last 7 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashfaq Shuaib, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashfaq Shuaib, MD FRCPC</last_name>
    <phone>780 407 3254</phone>
    <email>ashfaq.shuaib@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Khurshid Khan, MD FRCPC</last_name>
    <phone>780 407 7363</phone>
    <email>khurshid.khan@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ashfaq shuaib, MD FRCPC</last_name>
      <phone>780 407 3254</phone>
      <email>ashfaq.shuaib@ualberta.ca</email>
    </contact>
    <contact_backup>
      <last_name>Khurshid Khan, MD FRCPC</last_name>
      <phone>780 407 7363</phone>
      <email>khurshid.khan@ualberta.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2014</study_first_submitted>
  <study_first_submitted_qc>May 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>December 28, 2014</last_update_submitted>
  <last_update_submitted_qc>December 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Ashfaq Shuaib</investigator_full_name>
    <investigator_title>Professor of Neurology and Medicine</investigator_title>
  </responsible_party>
  <keyword>TIA</keyword>
  <keyword>stroke prevention</keyword>
  <keyword>ASA</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>dual antiplatelet treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

